INFI - Infinity Pharma updates data from bladder and breast cancer trials

luismmolina/E+ via Getty Images Infinity Pharmaceuticals (INFI) issued data updates from two mid-stage trials for eganelisib, the company’s oral immuno-oncology candidate. 49 patients were enrolled in the MARIO-275 study that was designed to evaluate it as a combination therapy with nivolumab (Opdivo) in platinum-refractory, I/O naïve patients with advanced urothelial cancer. In the combination arm, the median overall survival (mOS) in the intent to treat ((ITT)) population stood at 15.4 months versus 7.9 months on the control arm of nivolumab alone. At year one, 59% of patients in the ITT population receiving the combo were alive compared to 32% in the control arm. mOS benefit was similar across those with PD-L1(-) tumors and in the ITT population while most common treatment emergent adverse events (TEAEs) included pyrexia (33.3%) and decreased appetite (30.3%). There were no Grade 5 hepatic AEs, the company said. Meanwhile, the MARIO-3 was designed to evaluate eganelisib in

For further details see:

Infinity Pharma updates data from bladder and breast cancer trials